HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Structural and functional characterization of BnSP-7, a Lys49 myotoxic phospholipase A(2) homologue from Bothrops neuwiedi pauloensis venom.

Abstract
BnSP-7, a Lys49 myotoxic phospholipase A(2) homologue from Bothrops neuwiedi pauloensis venom, was structurally and functionally characterized. Several biological activities were assayed and compared with those of the chemically modified toxin involving specific amino acid residues. The cDNA produced from the total RNA by RT-PCR contained approximately 400 bp which codified its 121 amino acid residues with a calculated pI and molecular weight of 8.9 and 13,727, respectively. Its amino acid sequence showed strong similarities with several Lys49 phospholipase A(2) homologues from other Bothrops sp. venoms. By affinity chromatography and gel diffusion, it was demonstrated that heparin formed a complex with BnSP-7, held at least in part by electrostatic interactions. BnSP-7 displayed bactericidal activity and promoted the blockage of the neuromuscular contraction of the chick biventer cervicis muscle. In addition to its in vivo myotoxic and edema-inducing activity, it disrupted artificial membranes. Both BnSP-7 and the crude venom released creatine kinase from the mouse gastrocnemius muscle and induced the development of a dose-dependent edema. His, Tyr, and Lys residues of the toxin were chemically modified by 4-bromophenacyl bromide (BPB), 2-nitrobenzenesulfonyl fluoride (NBSF), and acetic anhydride (AA), respectively. Cleavage of its N-terminal octapeptide was achieved with cyanogen bromide (CNBr). The bactericidal action of BnSP-7 on Escherichia coli was almost completely abolished by acetylation or cleavage of the N-terminal octapeptide. The neuromuscular effect induced by BnSP-7 was completely inhibited by heparin, BPB, acetylation, and CNBr treatment. The creatine kinase releasing and edema-inducing effects were partially inhibited by heparin or modification by BPB and almost completely abolished by acetylation or cleavage of the N-terminal octapeptide. The rupture of liposomes by BnSP-7 and crude venom was dose and temperature dependent. Incubation of BnSP-7 with EDTA did not change this effect, suggesting a Ca(2+)-independent membrane lytic activity. BnSP-7 cross-reacted with antibodies raised against B. moojeni (MjTX-II), B. jararacussu (BthTX-I), and B. asper (Basp-II) myotoxins as well as against the C-terminal peptide (residues 115-129) from Basp-II.
AuthorsA M Soares, R Guerra-Sá, C R Borja-Oliveira, V M Rodrigues, L Rodrigues-Simioni, V Rodrigues, M R Fontes, B Lomonte, J M Gutiérrez, J R Giglio
JournalArchives of biochemistry and biophysics (Arch Biochem Biophys) Vol. 378 Issue 2 Pg. 201-9 (Jun 15 2000) ISSN: 0003-9861 [Print] United States
PMID10860537 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright 2000 Academic Press.
Chemical References
  • Crotalid Venoms
  • DNA, Complementary
  • Neurotoxins
  • Reptilian Proteins
  • Heparin
  • Peroxidase
  • Phospholipases A
  • Group II Phospholipases A2
  • Lys49-phospholipase A2, Bothrops neuwiedi pauloensis
  • Lysine
Topics
  • Amino Acid Sequence
  • Animals
  • Base Sequence
  • Bothrops (metabolism)
  • Chickens
  • Crotalid Venoms (chemistry)
  • DNA, Complementary (metabolism)
  • Dose-Response Relationship, Drug
  • Edema (metabolism)
  • Escherichia coli (metabolism)
  • Group II Phospholipases A2
  • Heparin (metabolism)
  • Lysine (chemistry)
  • Male
  • Mice
  • Molecular Sequence Data
  • Muscle, Skeletal (drug effects)
  • Neurotoxins (chemistry, genetics, toxicity)
  • Peroxidase (metabolism)
  • Phospholipases A (chemistry, genetics, toxicity)
  • Reptilian Proteins
  • Reverse Transcriptase Polymerase Chain Reaction
  • Sequence Homology, Amino Acid
  • Temperature
  • Time Factors
  • X-Ray Diffraction

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: